Source: Υπουργείο Υγείας (CY) Revision Year: 2018 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Pharmacotherapeutic group: Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD), H2-receptor antagonists
ATC code: A02BA03
Ulceran is a highly specific and potent competitive H2-receptors antagonist which is a reversible competitive blocker of histamine at H2 receptors, particularly those in the gastric parietal cells. The H2 antagonists are not anticholinergic agents and do not affect the H1 receptors. H2 antagonists inhibit all phases of gastric secretion cause by histamine, muscarinic agonists and gastrin.
Ulceran is orally administered. Famotidine preparations reach the peak plasma concentration within 1 to 3 hours after administration and the peak plasma concentration of a 40 mg dose is 0.076 to 0.1 mcg/ml. Plasma protein binding is low (15-20% and plasma half-life after a single dose or multiple repeated doses (for 5 days) was approximately 3 hours.
Plasma levels after multiple doses of famotidine are similar to those after single doses. Famotidine is eliminated by renal (65% to 70%) and metabolic (30% to 35%) routes. The only metabolite identified is the S-oxide. Approximately 25-60% of the oral dosage is excreted in the urine mainly as unchanged drug. A small amount maybe excreted as a sulfoxide.
No further relevant data.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
